Hologic Inc., a prominent women's health enterprise, has finalized its acquisition by investment funds spearheaded by Blackstone Inc. and TPG Inc. This significant transaction, valued at approximately $18.3 billion, marks a pivotal moment for Hologic as its common stock has ceased trading and been delisted from the Nasdaq Stock Market. The deal promises to inject substantial backing into Hologic's innovation and expansion efforts, ensuring continued advancement in the women's health sector.
Details of the Acquisition: Hologic's Transition and New Leadership
On April 8, 2026, the acquisition of Hologic by Blackstone and TPG reached its completion, following an agreement made in October 2025. The initial valuation of the deal was set at around $18.3 billion, representing a substantial 46% premium over Hologic's closing share price on May 23, 2025. Upon the transaction's conclusion, Hologic shareholders received $76 per share in cash. Additionally, they were issued a non-tradable contingent value right (CVR) that could yield up to an extra $3 per share, payable in two potential installments of up to $1.50 each. This CVR's payout is intrinsically linked to the performance of Hologic's Breast Health division, specifically its ability to achieve certain global revenue milestones in the fiscal years 2026 and 2027. This strategic move is anticipated to bolster Hologic's capacity for innovation and growth. Concurrently with the acquisition, the company announced a leadership transition: José E. Almeida has been appointed as the new chief executive officer, succeeding Stephen MacMillan, who retired after more than a decade of dedicated service as chairman, president, and CEO.
This acquisition underscores a broader trend in the healthcare industry, where strategic investments by private equity firms are aimed at fostering growth and technological advancement. For Hologic, this partnership with Blackstone and TPG could unlock new opportunities for research, development, and market penetration, ultimately benefiting women's health globally. The structured payout involving a CVR also reflects a forward-looking approach, aligning shareholder interests with the future success and performance of key business segments.